Stock 4534 MOCHIDA PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Mochida Pharmaceutical Co., Ltd.

Equities

4534

JP3922800002

Delayed Japan Exchange
Other stock markets
 08:38:51 2024-05-01 pm EDT 		5-day change 1st Jan Change
3,195 JPY -0.31% Intraday chart for Mochida Pharmaceutical Co., Ltd. +0.95% -2.29%
Apr. 25 Hidehiro Imatsu named president of Goldman Sachs Japan RE
Mar. 21 Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. CI

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The stock, which is currently worth 2024 to 0.5 times its sales, is clearly overvalued in comparison with peers.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company benefits from high valuations in earnings multiples.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
MOCHIDA PHARMACEUTICAL CO., LTD. Stock Mochida Pharmaceutical Co., Ltd.
-2.29% 719M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.25% 704B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+28.59% 577B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.55% 348B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.16% 327B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.36% 288B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.81% 234B
B+
NOVARTIS AG Stock Novartis AG
+4.93% 198B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
A+
AMGEN INC. Stock Amgen Inc.
-3.69% 147B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4534 Stock
  4. Ratings Mochida Pharmaceutical Co., Ltd.